Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) insider Arturo Molina sold 2,718 shares of the company’s stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $124.65, for a total transaction of $338,798.70. Following the transaction, the insider owned 81,397 shares in the company, valued at $10,146,136.05. The trade was a 3.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Protagonist Therapeutics Trading Down 2.5%
NASDAQ PTGX opened at $124.02 on Friday. The company has a fifty day simple moving average of $138.67 and a two-hundred day simple moving average of $119.98. The stock has a market cap of $8.09 billion, a P/E ratio of 26.94 and a beta of 1.21. Protagonist Therapeutics, Inc. has a 12-month low of $77.00 and a 12-month high of $160.81.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $3.07 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.57. The firm had revenue of $274.41 million for the quarter, compared to analyst estimates of $238.49 million. Protagonist Therapeutics had a net margin of 62.04% and a return on equity of 42.83%. As a group, sell-side analysts forecast that Protagonist Therapeutics, Inc. will post 5.52 earnings per share for the current year.
Hedge Funds Weigh In On Protagonist Therapeutics
Hedge funds have recently bought and sold shares of the business. Keating Financial Advisory Services Inc. purchased a new position in shares of Protagonist Therapeutics during the 2nd quarter valued at approximately $30,000. Allworth Financial LP purchased a new position in Protagonist Therapeutics in the 2nd quarter valued at $31,000. Quantbot Technologies LP acquired a new stake in Protagonist Therapeutics during the 2nd quarter worth $42,000. Parallel Advisors LLC boosted its stake in Protagonist Therapeutics by 205.9% during the 3rd quarter. Parallel Advisors LLC now owns 361 shares of the company’s stock worth $51,000 after purchasing an additional 243 shares during the last quarter. Finally, Harbor Investment Advisory LLC acquired a new stake in Protagonist Therapeutics during the 2nd quarter worth $89,000. Hedge funds and other institutional investors own 98.63% of the company’s stock.
Wall Street Analyst Weigh In
PTGX has been the subject of a number of research reports. Weiss Ratings upgraded Protagonist Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, November 4th. Wedbush reissued an “outperform” rating on shares of Protagonist Therapeutics in a report on Monday, November 9th. The Goldman Sachs Group upgraded Protagonist Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $110.00 to $186.00 in a research note on Monday, August 10th. BMO Capital Markets lifted their target price on Protagonist Therapeutics from $178.00 to $190.00 and gave the stock an “outperform” rating in a report on Tuesday, September 1st. Finally, Citigroup upped their target price on Protagonist Therapeutics from $175.00 to $182.00 and gave the company a “buy” rating in a research report on Monday, August 31st. One equities research analyst has rated the stock with a Strong Buy rating and sixteen have assigned a Buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $166.67.
View Our Latest Stock Analysis on PTGX
Protagonist Therapeutics Company Profile
Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.
Featured Articles
- Five stocks we like better than Protagonist Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
